이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Glenmark Pharmaceuticals 과거 수익 실적

과거 기준 확인 0/6

Glenmark Pharmaceuticals의 수입은 연평균 -34.4%의 비율로 감소해 온 반면, Pharmaceuticals 산업은 수입이 연평균 17%의 비율로 증가했습니다. 매출은 연평균 6%의 비율로 증가해 왔습니다.

주요 정보

-34.4%

수익 성장률

-34.4%

EPS 성장률

Pharmaceuticals 산업 성장	17.5%
매출 성장률	6.0%
자기자본 수익률	-23.3%
순이익	-16.1%
다음 실적 업데이트	14 Aug 2024

최근 과거 실적 업데이트

Recent updates

Calculating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

Aug 06

Does Glenmark Pharmaceuticals (NSE:GLENMARK) Have A Healthy Balance Sheet?

Jun 16

Is Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Expensive For A Reason? A Look At Its Intrinsic Value

May 08

Glenmark Pharmaceuticals (NSE:GLENMARK) Takes On Some Risk With Its Use Of Debt

Mar 09

Is Glenmark Pharmaceuticals (NSE:GLENMARK) Using Too Much Debt?

Dec 07

Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being

Sep 23

Glenmark Pharmaceuticals (NSE:GLENMARK) Will Pay A Dividend Of ₹2.50

Sep 17

Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50

Aug 30

A Look At The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

Aug 28

We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Is Taking Some Risk With Its Debt

Jul 03

An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 37% Undervalued

Oct 12

Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being

Sep 21

Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50

Aug 29

We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt

Jun 20

There May Be Reason For Hope In Glenmark Pharmaceuticals' (NSE:GLENMARK) Disappointing Earnings

Jun 04

An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 27% Undervalued

May 05

If You Like EPS Growth Then Check Out Glenmark Pharmaceuticals (NSE:GLENMARK) Before It's Too Late

Mar 25

A Look At The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

Jan 18

We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt

Dec 13

수익 및 비용 분석

Glenmark Pharmaceuticals 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

NSEI:GLENMARK 수익, 비용 및 수입 (INR Millions )
날짜	수익	수익	G+A 비용	R&D 비용
31 Mar 24	118,131	-18,990	28,681	0
31 Dec 23	131,575	-7,640	35,454	0
30 Sep 23	137,510	-1,263	34,998	0
30 Jun 23	136,144	2,546	28,740	0
31 Mar 23	129,901	2,972	33,653	0
31 Dec 22	126,355	8,811	31,713	0
30 Sep 22	123,451	8,305	30,013	0
30 Jun 22	121,173	8,277	24,874	0
31 Mar 22	123,049	9,417	29,176	0
31 Dec 21	122,103	10,202	28,735	0
30 Sep 21	118,248	10,464	28,841	0
30 Jun 21	116,144	10,226	24,305	0
31 Mar 21	109,439	9,700	28,103	0
31 Dec 20	107,778	9,565	29,386	0
30 Sep 20	107,445	8,992	28,992	0
30 Jun 20	106,629	9,207	22,777	0
31 Mar 20	106,573	7,760	28,627	0
31 Dec 19	104,370	7,173	29,403	0
30 Sep 19	102,564	6,428	28,861	0
30 Jun 19	100,227	7,680	20,903	0
31 Mar 19	98,655	9,250	28,738	0
31 Dec 18	95,532	8,863	26,688	0
30 Sep 18	92,018	8,721	26,317	0
30 Jun 18	89,057	6,716	19,400	0
31 Mar 18	90,744	8,039	25,149	0
31 Dec 17	91,908	6,420	25,123	0
30 Sep 17	95,055	10,083	24,474	0
30 Jun 17	94,896	10,233	23,733	0
31 Mar 17	90,794	9,160	23,601	0
31 Dec 16	89,316	10,402	21,486	0
30 Sep 16	81,749	7,508	20,918	0
30 Jun 16	78,414	7,292	20,078	0
31 Mar 16	75,732	7,021	19,219	0
31 Dec 15	70,300	5,697	25,618	1,624
30 Sep 15	69,530	5,141	25,335	1,624
30 Jun 15	67,244	4,814	24,904	1,624
31 Mar 15	65,561	4,753	15,454	0
31 Dec 14	64,891	5,078	21,404	1,414
30 Sep 14	63,983	6,092	20,973	1,414
30 Jun 14	61,897	5,984	20,065	1,414
31 Mar 14	59,450	5,423	19,409	1,414
31 Dec 13	56,441	6,660	9,575	0
30 Sep 13	54,241	6,627	8,964	0

양질의 수익: GLENMARK 은(는) 현재 수익성이 없습니다.

이익 마진 증가: GLENMARK 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: GLENMARK 은(는) 수익성이 없으며 지난 5년 동안 연간 34.4% 비율로 손실이 증가했습니다.

성장 가속화: 현재 수익성이 없기 때문에 GLENMARK 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: GLENMARK 은(는) 수익성이 없어 지난 해 수익 성장을 Pharmaceuticals 업계( 18% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: GLENMARK 현재 수익성이 없기 때문에 마이너스 자본 수익률( -23.33% )을 갖습니다.

Glenmark Pharmaceuticals 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

Glenmark Pharmaceuticals Limited to Report Q1, 2025 Results on Aug 14, 2024

Full year 2024 earnings: EPS and revenues miss analyst expectations

Glenmark Pharmaceuticals Limited to Report Q4, 2024 Results on May 24, 2024

Third quarter 2024 earnings released: ₹16.66 loss per share (vs ₹9.66 profit in 3Q 2023)

Glenmark Pharmaceuticals Limited to Report Q3, 2024 Results on Feb 14, 2024

Glenmark Pharmaceuticals Limited to Report Q2, 2024 Results on Nov 10, 2023

Recent updates

Calculating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

Glenmark Pharmaceuticals Limited to Report Q1, 2025 Results on Aug 14, 2024

Does Glenmark Pharmaceuticals (NSE:GLENMARK) Have A Healthy Balance Sheet?

Price target increased by 9.7% to ₹1,056

Full year 2024 earnings: EPS and revenues miss analyst expectations

Glenmark Pharmaceuticals Limited Recommends Dividend for the Financial Year 2023-24

Glenmark Pharmaceuticals Receives ANDA Approval for Brimonidine Tartrate and Timolol Maleate Ophthalmic Solution, 0.2%|0.5%

Glenmark Pharmaceuticals Limited to Report Q4, 2024 Results on May 24, 2024

Is Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Expensive For A Reason? A Look At Its Intrinsic Value

Now 24% overvalued after recent price rise

Nirma Limited completed the acquisition of 75% stake in Glenmark Life Sciences Limited (NSEI:GLS) from Glenmark Pharmaceuticals Limited (NSEI:GLENMARK) (GPL).

Glenmark Pharmaceuticals (NSE:GLENMARK) Takes On Some Risk With Its Use Of Debt

Price target increased by 11% to ₹907

Now 20% overvalued after recent price rise

Now 21% overvalued after recent price rise

Third quarter 2024 earnings released: ₹16.66 loss per share (vs ₹9.66 profit in 3Q 2023)

Glenmark Pharmaceuticals Limited to Report Q3, 2024 Results on Feb 14, 2024

Is Glenmark Pharmaceuticals (NSE:GLENMARK) Using Too Much Debt?

Glenmark Pharmaceuticals Limited to Report Q2, 2024 Results on Nov 10, 2023

Glenmark Pharma Launches Triple-Drug FDC of Teneligliptin + Dapagliflozin + Metformin in India for Type 2 Diabetes in Adults with Co-Morbidities

Glenmark Pharmaceuticals Receives ANDA Approval for Apremilast Tablets, 10 Mg, 20 Mg and 30 Mg

Nirma Limited entered into a definitive agreement to acquire 75% stake in Glenmark Life Sciences Limited (NSEI:GLS) from Glenmark Pharmaceuticals Limited (NSEI:GLENMARK) for INR 56.5 billion.

Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being

Glenmark Pharmaceuticals Divests 75% in GLS to Nirma

Glenmark Pharmaceuticals (NSE:GLENMARK) Will Pay A Dividend Of ₹2.50

Glenmark Pharmaceuticals Limited Announces Management Promotions

Upcoming dividend of ₹2.50 per share at 0.3% yield

Insufficient new directors

Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50

A Look At The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

Glenmark Pharmaceuticals Limited, Annual General Meeting, Sep 29, 2023

ChrysCapital Still in Race to Buy Controlling Stake in Glenmark Life Sciences

Price target increased by 12% to ₹689

First quarter 2024 earnings released: EPS: ₹5.31 (vs ₹6.82 in 1Q 2023)

Glenmark Pharmaceuticals Limited to Report Q1, 2024 Results on Aug 11, 2023

Nirma, Sekhmet Pharmaventures Reportedly Vie for $731 Million Glenmark Life Stake

We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Is Taking Some Risk With Its Debt

Miller Law LLC and Motley Rice LLC Announce a Proposed Settlement in re Zetia (Ezetimibe) Antitrust Litigation

A Look At The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

Full year 2023 earnings released: EPS: ₹10.53 (vs ₹33.37 in FY 2022)

Glenmark Pharmaceuticals Limited Recommends Dividend for the Financial Year 2022-23

Glenmark Pharmaceuticals (NSE:GLENMARK) Has A Somewhat Strained Balance Sheet

Estimating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

Third quarter 2023 earnings released: EPS: ₹9.66 (vs ₹7.86 in 3Q 2022)

Glenmark Pharmaceuticals Limited Launches in India Unique I.V. Injection Formulation

Glenmark Pharmaceuticals Launches the Sacubitril + Valsartan Tablets in India for the Treatment of Heart Failure

Glenmark Pharmaceuticals Limited to Report Q3, 2023 Results on Feb 10, 2023

Glenmark Pharmaceuticals Limited Receives Final Approval by United States Food & Drug Administration for Nicardipine Hydrochloride Capsules, 20 Mg and 30 Mg

J. B. Chemicals & Pharmaceuticals Limited (BSE:506943) agreed to acquire Razel Franchise For India And Nepal Region from Glenmark Pharmaceuticals Limited (NSEI:GLENMARK) for INR3.1 billion.

Second quarter 2023 earnings released: EPS: ₹9.23 (vs ₹9.13 in 2Q 2022)

Insufficient new directors

Second quarter 2023 earnings released: EPS: ₹9.23 (vs ₹9.13 in 2Q 2022)

Glenmark Pharmaceuticals Limited to Report Q2, 2023 Results on Nov 11, 2022

Glenmark Pharmaceuticals Limited to Launch Teneligliptin + Dapagliflozin Fixed Dose Combination, for Adults with Type 2 Diabetes, Having Comorbidities

An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 37% Undervalued

Glenmark Launches Lobeglitazone in India for Uncontrolled Type 2 Diabetes in Adults

Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being

Upcoming dividend of ₹2.50 per share

Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50

Glenmark Pharmaceuticals Limited, Annual General Meeting, Sep 27, 2022

Glenmark Pharmaceuticals Limited, Annual General Meeting, Sep 27, 2022

First quarter 2023 earnings released: EPS: ₹6.82 (vs ₹10.86 in 1Q 2022)

Glenmark Pharmaceuticals Limited to Report Q1, 2023 Results on Aug 10, 2022

Glenmark Pharmaceuticals Limited and SaNOtize Research and Development Corp. Announces Peer Reviewed Publication of Its Phase 3 Clinical Trials on Sanotize's Novel Nitric Oxide Nasal Spray for Covid-19 in Lancet Journal

Glenmark Pharmaceuticals Ltd. Launch's India's First Topical Minocycline 4% Gel for the Treatment of Moderate to Severe Acne

Glenmark Pharmaceuticals Limited Launches Sitagliptin and its Fixed Dose Combinations for Adults with Type 2 Diabetes in India

Upcoming dividend of ₹2.50 per share

We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt

Glenmark Pharmaceuticals Limited Launches Novel Fixed-Dose Combination Drug - Indacaterol + Mometasone for Patients Suffering from Uncontrolled Asthma, in India